Literature DB >> 6357075

Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography.

C M Myers, J L Blumer.   

Abstract

Ceftazidime is a new beta-lactamase-stable third-generation cephalosporin with a broad spectrum of antimicrobial activity. To evaluate the biodisposition of the drug in infants and children, a rapid and simple high-pressure liquid chromatographic technique was developed. The method is useful for both serum and urine and involves methanol precipitation followed by reverse-phase chromatography on MicroPak MCH 10. The mobile phase, consisting of 20% methanol and an 80% aqueous solution of 50 mM ammonium dihydrogen phosphate and 117 microM perchloric acid, is pumped at 1 ml/min through the column which is maintained at 50 degrees C. The drug was detected at 257 nm with a variable-wavelength UV detector. A good linear correlation was observed between the peak area and the ceftazidime concentration at 0.3 to 500 micrograms/ml (r = 0.999). Since an equal volume of cold methanol is used to precipitate proteins from serum samples and only 20 microliters of the resultant supernatant is injected into the column, samples as small as 50 microliters may be routinely analyzed. This method has been used to study ceftazidime pharmacokinetics in more than 30 patients and has proven to be rapid and reproducible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357075      PMCID: PMC185323          DOI: 10.1128/AAC.24.3.343

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

Authors:  A D Kashuba; C H Ballow; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 3.  Penicillins and cephalosporins. Physicochemical properties and analysis in pharmaceutical and biological matrices.

Authors:  P C Van Krimpen; W P Van Bennekom; A Bult
Journal:  Pharm Weekbl Sci       Date:  1987-02-20

4.  Recent analytical methods for cephalosporins in biological fluids.

Authors:  R D Toothaker; D S Wright; L A Pachla
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

5.  Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation.

Authors:  I W Fong; K B Tomkins
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

6.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

7.  Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.

Authors:  Cassio Girardi; Marc Tonnellier; Ivan Goldstein; Alfonso Sartorius; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2006-07-21       Impact factor: 17.440

8.  Pharmacokinetic profiles of ceftazidime after intravenous administration in patients undergoing automated peritoneal dialysis.

Authors:  Kiwon Kim; Young-Hwan Hwang; Han Ro; Yun Kyu Oh; Min-Gul Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Sang Goo Shin; Curie Ahn; Kook-Hwan Oh
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

9.  Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Authors:  Fabio Ferrari; Qin Lu; Cassio Girardi; Olivier Petitjean; Charles-Hugo Marquette; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2009-08-04       Impact factor: 17.440

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.